BearishMEDIUM severityFinancials5d ago

Blackstone to provide Pfizer up to $1.5B to advance monthly GLP-1 for weight loss

Blackstone to provide Pfizer up to $1.5B to advance monthly GLP-1 for weight loss — $BX one-month chart
$BX daily closes over the past month · Wook of Wall Street artwork from market data

At a glance

WOOKAI ASSISTANTREADY
WOOK AIASK ANYTHING · NEVER ADVISES

Ask about BX. Get explanations, comparisons and calculations with the source lookups shown.

Risk check · BlackstoneEvent risk Low

Nothing reported about Blackstone across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.

From here · options-implied volatility 42% a year
Now $116.48Week $109.58–$123.38 (±5.9%)Month $102.35–$130.61 (±12.1%)

Options price an average move of ±9.4% by Dec 18 — the at-the-money straddle, the typical size of the move; the bands are one standard deviation.

Ask Wook AI

Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.

Wook analysis

What it means

Key points
  • What to watch: The headline hinges on a single figure — $1.5B — but the real story lies in the broader trend, not just the snapshot.
  • How the stocks are trading: $BX -0.01%, $PFE -1.42% in the latest session.
  • Timing: It came out after the closing bell. The session change shown was settled before the story existed, and the next session is the first that could react.
Amount$1.5 billion

Where the stock stands

Blackstone ($BX) slipped 0.01% to $117.00 in the latest session. Over the past month it is up 8.8%. It now sits 29% under the 52-week high of $165.14 and 15% above the year's low of $101.73. Its 52-week range spans 62% from low to high, so weekly moves of several percent are normal. Pfizer ($PFE) declined 1.42% to $28.45 in the latest session. Over the past month it is down 3.3%. It now sits 9.5% under the 52-week high of $31.44 and 20% above the year's low of $23.62. The high sits 33% above the low, a moderate range for a year.

What the filings say

In its latest report (10-Q, filed Nov 6, 2026), $BX earned $662.4M over the quarter to Sep 30, 2026 on revenue of $3.06B (-39.3% QoQ). Operations brought in $4.90B of cash over the nine months to Sep 30, 2026; after capital spending, free cash flow was $4.78B. It carried $13.52B of debt against $3.04B of cash on Sep 30, 2026 — net debt of $10.48B. Its most recent filings before this story: 10-Q on Nov 6, 2026, 8-K on Nov 2, 2026, 8-K on Oct 27, 2026. Figures are as filed with the SEC; the $BX page has the full statements.

How much coverage it is getting

This is one of 43 stories on these companies in Wook's last 30 days of coverage, including 8 this week. Its 30-day average is about 10 a week, so this week is quieter than usual. Going by their wording, 30% read bullish, 65% neutral and 5% bearish. This one reads bearish, against the grain of most of it. Seeking Alpha wrote 28 of the 43 (65%), so the count reflects one outlet's output more than broad attention.

The bigger picture

Financial news often turns on rates, credit, and capital: how much lenders earn versus how much they pay, and how much capital regulators demand. Wook's supply-chain scanner has Financials on watch today, which means early signs of strain worth keeping an eye on.

Coming up

$BX earnings in 72 days and $PFE earnings in 77 days. These dates were set well before this story broke.

What to watch next

Check $BX's SEC filings for the full story. Most recent coverage comes from one outlet — verify with another. Ask Wook AI about $BX's recent performance or coverage shifts for deeper insight.

Discussion

No one has weighed in yet. Start the discussion on this story.

What happened after this published

Seeking Alpha published this on November 11, 2026. $BX has moved -4.49% ($122.50 to $117.00) and $PFE has moved -3.46% ($29.47 to $28.45). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.

Headline and link are attributed to Seeking Alpha. Wook of Wall Street is an independent research tool and is not affiliated with Seeking Alpha. Nothing here is financial advice or a recommendation — research and educational content only.

Choose what Wook may measure. Essential sign-in and security cookies stay on.

Read the privacy policy